Nivalis Therapeutics Prices IPO At $14.00/shr

(RTTNews) - Nivalis Therapeutics Inc. (NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis, announced that it has priced its initial public offering of 5.5 million shares of its common stock at a price to the public of $14.00 per share, before underwriting discounts and commissions.

In addition, Nivalis has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

All shares of the common stock in this offering are being sold by Nivalis. Nivalis' shares are expected to begin trading on The NASDAQ Global Market on June 17, 2015 under the ticker symbol "NVLS." This offering is expected to close on June 22, 2015, subject to customary closing conditions.

Cowen and Company and Stifel are acting as joint lead book-running managers for the offering. Baird and H.C. Wainwright & Co. are acting as co-managers for the offering.